PET100-Related Cytochrome c Oxidase (Complex IV) Deficiency — Deep Research Report

Disease: PET100-Related COX Deficiency (mitochondrial complex IV deficiency, nuclear type 12; MC4DN12) MONDO: MONDO:0033646  |  OMIM phenotype: 619055  |  Gene: PET100 (HGNC:40038; formerly C19orf79)  |  Inheritance: autosomal recessive

Executive Summary

PET100-related Complex IV (cytochrome c oxidase, COX) deficiency is an ultra-rare autosomal recessive mitochondrial disorder caused by biallelic loss-of-function variants in the small nuclear-encoded inner-mitochondrial-membrane Complex IV biogenesis factor PET100 (formerly C19orf79). PET100 forms a ~300 kDa subcomplex with COX subunits and is required for their incorporation into the maturing holoenzyme; its loss produces an isolated Complex IV biogenesis defect.

The primary human literature is small and, after this sweep, considered essentially complete. It comprises three primary reports:

1. Lim et al., 2014 (PMID:24462369, Am J Hum Genet) — the founder report: eight Complex IV-deficient Leigh syndrome individuals from six Lebanese families homozygous for the initiation-codon allele c.3G>C (p.Met1?); seizures prominent (distinguishing them from SURF1 disease). PET100 localized to the inner membrane forming a ~300 kDa subcomplex with COX subunits.
2. Oláhová et al., 2015 (PMID:25293719, Eur J Hum Genet) — a single non-Lebanese (British Pakistani) neonate homozygous for the truncating allele c.142C>T (p.Gln48*) with fatal neonatal-onset multiorgan disease: severe lactic acidosis, microcephaly, hypoglycemia, generalized aminoaciduria, coagulopathy/hypoalbuminemia ("severely impaired liver function"), and raised creatine kinase. This extended the phenotype beyond the founder population.
3. Mansour et al., 2019 (PMID:31406627, J Pediatr Genet) — newly surfaced by this sweep; was NOT cited in the original entry. Two further Lebanese families (one consanguineous), four affected siblings total, again carrying the founder c.3G>C (p.Met1?) allele, with developmental delay, seizures, lactic acidosis, abnormal brain MRI, low (~30%) muscle Complex IV activity, and in the more severe sibship failure to thrive, muscular hypotonia, developmental regression, and respiratory insufficiency.

A GeneReviews overview, Nuclear Gene-Encoded Leigh Syndrome Spectrum Overview (PMID:26425749), provides authoritative baseline context for the Leigh syndrome spectrum to which PET100 disease belongs and has been added as a tagged top-level reference.

No curative therapy exists; management is supportive (seizure control, buffering of metabolic acidosis, developmental support).

1. Literature Completeness Check (the point of this sweep)

Two independent WebSearch queries (gene/disorder synonyms; recent-cohort framing 2020–2025) returned no additional primary clinical reports beyond the three above. The 2020–2025 sweep surfaced only secondary resources (GeneCards, OMIM #619055, GTR, PreventionGenetics test pages) — no new patient cohorts — supporting the conclusion that the primary literature is near-complete and dominated by the Lebanese founder allele.

2. Gene and Protein Function

• PET100 (formerly C19orf79) encodes a small (~9 kDa) Complex IV biogenesis factor localized to the mitochondrial inner membrane, exposed to the intermembrane space. It forms a ~300 kDa subcomplex with COX subunits and acts at an intermediate stage of holoenzyme assembly (PMID:24462369). In yeast the homolog acts late in COX assembly; human PET100 appears required earlier, for assembly of mtDNA-encoded COX subunits (PMID:25293719 discussion).
• Loss of PET100 destabilizes COX subunits and blocks assembly of fully formed Complex IV, yielding isolated Complex IV deficiency (other OXPHOS complexes intact on BN-PAGE).

3. Genotype–Phenotype Notes

• c.3G>C (p.Met1?) — Lebanese founder allele; infantile-onset Leigh / Leigh-like syndrome with prominent seizures, developmental delay, variable lactic acidosis, basal ganglia lesions; residual muscle COX activity ~30%. Recurs across Lebanese families (PMID:24462369, PMID:31406627).
• c.142C>T (p.Gln48*) — single truncating allele; far more severe, prenatal-onset with neonatal death, extreme lactic acidosis (peak 63 mmol/l), microcephaly, multiorgan involvement (hepatic, renal, skeletal muscle) not seen with the founder allele (PMID:25293719).

4. Treatment

No disease-modifying therapy. Supportive/metabolic care only (bicarbonate/THAM buffering of acute acidosis, anticonvulsants, developmental support) — consistent across all reports.

Caveats

• This was a focused completeness sweep, not the full multi-angle adversarial harness; it was scoped to the literature-gap question the reviewer raised. All clinical claims used as evidence in the YAML are independently snippet-validated against just fetch-reference-cached primary sources via just validate-references.
• The primary literature is dominated by a single founder allele in one population; generalization of genotype–phenotype correlations is limited by small N (~13 reported individuals total across three papers).